Following the news that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has secured FDA approval in a major way for its pipeline drug Spinraza in the indication …
McKesson Corporation McKesson Corporation (NYSE:MCK) shares are falling nearly 22% today after the company reported disappointing results for the fiscal second-quarter and issued lackluster guidance. MCK posted …
In a research report released yesterday, Leerink Swann analyst Seamus Fernandez reiterated an Outperform rating on shares of Bristol-Myers Squibb Co (NYSE:BMY), after the …
Illumina, Inc. Illumina, Inc.
In a research report released on Monday, Leerink top analyst Michael Schmidt initiated coverage on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) with a price …
Leerink Swann analyst, Michael Schmidt, reiterates his Outperform rating on bluebird bio Inc (NASDAQ:BLUE) after the company reported its 2Q16 financial results. The analyst couples his …
Leerink Swann analyst Danielle Antalffy reiterates an Outperform rating on Edwards Lifesciences Corp (NYSE:EW) following the company’s better than-expected sales report, marking the company’s 9th …
Analyst Michael Schmidt from Leerink Swann shared his thoughts on Juno Therapeutics Inc (NASDAQ:JUNO), following its $10 million acquisition of RedoxTherapies. In addition to …
On Wednesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) hosted an R&D day in NYC, where it framed the antisense/IONS vs RNAi debate particularly as it pertains to …
Leerink Swann analyst Michael Schmidt was out pounding the table on Exelixis, Inc. (NASDAQ:EXEL) Tuesday, reiterating an Outperform rating and price target of $10, which represents a potential upside …